Melek YILDIZ, Özlem NALBANTOĞLU, Nilüfer ÇELİK, Figen İŞLETEN, Birsen TUĞLU, Behzat ÖZKAN, Korcan DEMİR, Hüseyin Anıl KORKMAZ

Anti-cyclic citrullinated peptide antibodies are not frequently observed in children with type 1 diabetes mellitus: a single- center study

Yıldız M, İşleten F, Demir K, Çelik N, Korkmaz HA, Tuğlu B, Nalbantoğlu Ö, Özkan B. Anti-cyclic citrullinated peptide antibodies are not frequently observed in children with type 1 diabetes mellitus: A single-center study. Turk J Pediatr 2016; 58: 395-399.Type 1 diabetes mellitus (DM) and rheumatoid arthritis (RA) have been reported to occur concurrently in some cases. This study aimed to evaluate the presence of anti-cyclic citrullinated peptide (CCP) antibodies, which have been reported to have diagnostic value for RA, in children with type 1 DM. The study included 90 children with type 1 DM (Group 1) and 76 control cases (Group 2). The rates of reported family histories of RA and rheumatoid factor positivity did not differ between groups. In group 1, one case (1.1%) was positive for anti-CCP antibodies, whereas none of the controls were positive. The anti-CCP positive patient had no relevant joint complaints. Anti-CCP antibodies were rarely found in cases of pediatric type 1 DM. Thus, relevant screening in the follow-up of pediatric patients does not appear to be rational in the absence of any signs or symptoms of arthritis. The single case exhibiting a high anti-CCP level needs to be followed up for RA, although this positive result might be nonspecific and transient.

PDF

___

1. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-1436.
2. Karavanaki K, Kakleas K, Paschali E, et al. Screening for associated autoimmunity in children and adolescents with type 1 diabetes mellitus (T1DM). Horm Res 2009; 71: 201-206.
3. Agrawal S, Desai MP. Simultaneous occurrence of type I diabetes mellitus and juvenile rheumatoid arthritis. Indian Pediatr 2003; 40: 568-571.
4. Somers EC, Thomas SL, Smeeth L, Hall AJ. Autoimmune diseases co-occurring within individuals and within families: a systematic review. Epidemiology 2006; 17: 202-217.
5. Criswell LA, Pfeiffer KA, Lum RF, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 2005; 76: 561-571.
6. Kallberg H, Padyukov L, Plenge RM, et al. Genegene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80: 867-875.
7. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006; 65: 845-851.
8. Liao KP, Gunnarsson M, Kallberg H, et al. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. Arthritis Rheum 2009; 60: 653-660.
9. Desplat-Jego S, Deharveng I, Baronne R, Valero R, Begu-Le Corroller A, Vialettes B. Antibodies to cyclic citrullinated peptides (anti-CCP) in Type 1 diabetes mellitus. Diabet Med 2010; 27: 725-727.
10. Tasliyurt T, Kisacik B, Kaya SU, et al. The frequency of antibodies against cyclic citrullinated peptides and rheumatoid factor in healthy population: a field study of rheumatoid arthritis from northern Turkey. Rheumatol Int 2013; 33: 939-942.
11. Li T, Bao J, Yin J, Xu HJ. [The specificity of anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis from a large cohort study in the Chinese]. Zhonghua Nei Ke Za Zhi 2011; 50: 99-101.
12. Goeldner I, Skare TL, de Messias Reason IT, Nisihara RM, Silva MB, Utiyama SR. Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in rheumatoid arthritis patients and relatives from Brazil. Rheumatology (Oxford) 2010; 49: 1590-1593.
13. Nisihara RM, Skare TL, Silva MB, et al. High positivity of anti-CCP antibodies in patients with Down syndrome. Clin Rheumatol 2007; 26: 2031-2035.
14. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Cancers and immune related diseases associated with Down's syndrome: a record linkage study. Arch Dis Child 2004; 89: 1014-1017.
15. Craig ME, Jefferies C, Dabelea D, Balde N, Seth A, Donaghue KC. Definition, epidemiology, and classification of diabetes in children and adolescents. Pediatr Diabetes 2014; (15 Suppl)20: 4-17.
16. Hakala M, Ilonen J, Reijonen H, Knip M, Koivisto O, Isomaki H. No association between rheumatoid arthritis and insulin dependent diabetes mellitus: an epidemiologic and immunogenetic study. J Rheumatol 1992; 19: 856-858.
17. Berglin E, Padyukov L, Sundin U, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6: R303-R308.
18. Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 2006; 33: 647- 651.
19. Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 733-741.